Company intelligence / Profile preview
Allgenesis Biotherapeutics
Taipei City, Taipei City, Taiwanis.linkedin.com ↗
- Ownership
- Private
- Employees
- ~8
- Development stage
- Phase 2
01
Overview
Allgenesis Biotherapeutics has reported encouraging preliminary safety and efficacy data from its Phase 2a trial of AG‑73305 in diabetic macular edema. AG‑73305 showed a mean improvement in BCVA (+6.4 ETDRS letters) and CST reduction (-100 microns) at four weeks post-injection, with effects lasting up to six months after a single dose. No dose-limiting toxicities or serious adverse events related to the drug were observed. The company’s dry eye candidate AG‑80308 also demonstrated safety and improvements in both signs and symptoms in a Phase 1b trial.
- Therapeutic areas
- Ophthalmology
- Modalities
- Multi-specific fusion proteins (e.g., Fc-fusion proteins)Small molecule drugsFormyl peptide receptor agonists
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →03
Partnerships
AffaMed Therapeutics – licensing agreement for development/commercialization of AG–73305 in Greater China, South Korea, ASEAN markets.
Beyond the preview
Go deeper on Allgenesis Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Allgenesis Biotherapeutics.